Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017
07 sept. 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...